Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer
Lior Rosenfeld, Amiram Sananes, Yuval Zur, Shira Cohen, Kalyan Dhara, Sigal Gelkop, Efrat Ben Zeev, Anat Shahar, Leslie Lobel, Barak Akabayov, Eyal Arbely, Niv Papo
Abstract
studies show that the extent of tumor growth inhibition is similar when mice are treated with commercial doxorubicin and with a 42-fold lower amount of the nanobody-conjugated doxorubicin, attesting to the efficacy of the conjugated drug. These data highlight nanobodies as promising agents for the imaging of PCa tumors and for the targeted delivery of chemotherapeutic drugs.
Topics & Concepts
DoxorubicinProstate cancerGlutamate carboxypeptidase IIChemistryCancer researchInternalizationCytotoxic T cellIn vivoDrug deliveryProstateConjugateTargeted drug deliveryAntigenCancerPharmacologyIn vitroChemotherapyMedicineImmunologyInternal medicineBiochemistryBiologyCellMathematicsOrganic chemistryBiotechnologyMathematical analysisMonoclonal and Polyclonal Antibodies ResearchRadiopharmaceutical Chemistry and ApplicationsGlycosylation and Glycoproteins Research